Who is sponsoring NCT04615715?

NCT04615715 is sponsored by University of Alabama at Birmingham.

What drugs are being tested in NCT04615715?

Interventions in NCT04615715: CMV Risk-Reduction Intervention, Stress Reduction Messaging.

What condition does NCT04615715 study?

NCT04615715 studies Maternal Cytomegalovirus Infections, Cytomegalovirus Congenital.

Is NCT04615715 still recruiting?

NCT04615715 is currently completed. Last updated 3 April 2026.

Last reviewed 2026-04-03 · How we verify

NCT04615715

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prenatal Behavioral Intervention to Prevent Maternal Cytomegalovirus (CMV) in Pregnancy

Completed NA Last updated 3 April 2026

What this trial tests

NA trial testing CMV Risk-Reduction Intervention in Maternal Cytomegalovirus Infections in 582 participants. Completed in 31 March 2026.

Timeline

11 January 2021

Primary endpoint
31 March 2026

31 March 2026

Quick facts

Lead sponsor	University of Alabama at Birmingham
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	prevention
Enrollment	582
Start date	11 January 2021
Primary completion	31 March 2026
Estimated completion	31 March 2026
Sites	1 location across United States

Drugs / interventions tested

CMV Risk-Reduction Intervention
Stress Reduction Messaging

Conditions studied

Maternal Cytomegalovirus Infections — all drugs for Maternal Cytomegalovirus Infections →
Cytomegalovirus Congenital — all drugs for Cytomegalovirus Congenital →

Sponsor

University of Alabama at Birmingham

Who can join

Adults 14 to 39, female only, with Maternal Cytomegalovirus Infections or Cytomegalovirus Congenital. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will evaluate whether a brief prenatal clinic-based cytomegalovirus (CMV) risk-reduction behavioral intervention will prevent maternal CMV infections during pregnancy in women.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Emerging Concepts in Congenital Cytomegalovirus.
Pesch MH, Schleiss MR. · · 2022 · cited 45× · PMID 35909155 · DOI 10.1542/peds.2021-055896

Verify or expand the search:

Other University of Alabama at Birmingham trials

Trials by the same sponsor.

NCT04922229 — Comparative Effectiveness in the Management of Irreversible Pulpitis · NA · not yet recruiting
NCT05060380 — Feasibility of a Novel Resistance Exercise in Individuals With Osteoporosis · NA · withdrawn
NCT04768777 — Behavioral Intervention for Physical Activity and Sexual Dysfunction in Multiple Sclerosis · NA · not yet recruiting
NCT06320951 — VITAL-IMPACT: Improving Cardiometabolic Health in Black Individuals Through Therapeutic Augmentation of Cyclic Guanosine · Phase 2 · not yet recruiting
NCT07564934 — Leveraging Extended Reality Exergaming and Telehealth to Improve Physical Activity and Health in Children With Disabilit · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04615715 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Alabama at Birmingham
Last refreshed: 3 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04615715.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing